BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jeong JY, Kim B, Ji SY, Baek YC, Kim M, Park SH, Jung H. Effect of Flutriafol Exposure on Residue Characteristics in Pig Muscle and Fat Tissue. Food Sci Anim Resour 2022;42:186-96. [PMID: 35028583 DOI: 10.5851/kosfa.2021.e61] [Reference Citation Analysis]
2 Chu X, Li L, Yan W, Ma H, Maciejczyk M. 4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes. Oxidative Medicine and Cellular Longevity 2022;2022:1-15. [DOI: 10.1155/2022/5180242] [Reference Citation Analysis]
3 Wei J, Fang D. Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma. Int J Mol Sci 2021;22:1799. [PMID: 33670323 DOI: 10.3390/ijms22041799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Krisnamurti DGB, Purwaningsih EH, Tarigan TJE, Nugroho CMH, Soetikno V, Louisa M. Alterations of Liver Functions and Morphology in a Rat Model of Prediabetes After a Short-term Treatment of a High-fat High-glucose and Low-dose Streptozotocin. Open Access Maced J Med Sci 2022;10:668-74. [DOI: 10.3889/oamjms.2022.8717] [Reference Citation Analysis]
5 Zhou Y, Wu C, Wang X, Li P, Fan N, Zhang W, Liu Z, Zhang W, Tang B. Exploring the Changes of Peroxisomal Polarity in the Liver of Mice with Nonalcoholic Fatty Liver Disease. Anal Chem 2021;93:9609-20. [PMID: 34191493 DOI: 10.1021/acs.analchem.1c01776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang W, Liu X, Wei P, Ye F, Chen Y, Shi L, Zhang X, Li J, Lin S, Yang X. SPP1 and CXCL9 Promote Non-alcoholic Steatohepatitis Progression Based on Bioinformatics Analysis and Experimental Studies. Front Med 2022;9:862278. [DOI: 10.3389/fmed.2022.862278] [Reference Citation Analysis]
7 Passos E, Pereira C, Gonçalves IO, Faria A, Ascensão A, Monteiro R, Magalhães J, Martins MJ. Physical exercise positively modulates nonalcoholic steatohepatitis-related hepatic endoplasmic reticulum stress. J Cell Biochem 2022. [PMID: 35467032 DOI: 10.1002/jcb.30250] [Reference Citation Analysis]
8 Kim HY, Yoo YH. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression. IJMS 2022;23:8899. [DOI: 10.3390/ijms23168899] [Reference Citation Analysis]
9 Bhave S, Ho HK. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1776. [PMID: 34944593 DOI: 10.3390/biomedicines9121776] [Reference Citation Analysis]
10 Talukdar S, Kharitonenkov A. FGF19 and FGF21: In NASH we trust. Mol Metab 2021;46:101152. [PMID: 33383173 DOI: 10.1016/j.molmet.2020.101152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Jiang Y, Sui D, Li M, Xu H, Yu X, Liu J, Yu Q. Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. Evid Based Complement Alternat Med 2021;2021:9003603. [PMID: 34659439 DOI: 10.1155/2021/9003603] [Reference Citation Analysis]
12 Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. Yonsei Med J 2022;63:619-31. [PMID: 35748073 DOI: 10.3349/ymj.2022.63.7.619] [Reference Citation Analysis]
13 Collazo N, Carpena M, Nuñez-Estevez B, Otero P, Simal-Gandara J, Prieto MA. Health Promoting Properties of Bee Royal Jelly: Food of the Queens. Nutrients 2021;13:543. [PMID: 33562330 DOI: 10.3390/nu13020543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Wang X, Li W, Fu J, Ni Y, Liu K, Liu F. Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-8. [DOI: 10.1155/2022/6250751] [Reference Citation Analysis]
15 Zhang C, Liu S, Yang M. The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Gastroenterology Insights 2022;13:148-61. [DOI: 10.3390/gastroent13020016] [Reference Citation Analysis]
16 Ramos MJ, Bandiera L, Menolascina F, Fallowfield JA. In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. iScience 2022;25:103549. [PMID: 34977507 DOI: 10.1016/j.isci.2021.103549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kurdiova T, Balaz M, Kovanicova Z, Zemkova E, Kuzma M, Belan V, Payer J, Gasperikova D, Dieplinger H, Ukropcova B, Ukropec J. Serum Afamin a Novel Marker of Increased Hepatic Lipid Content. Front Endocrinol (Lausanne) 2021;12:670425. [PMID: 34603196 DOI: 10.3389/fendo.2021.670425] [Reference Citation Analysis]
18 Dorairaj V, Sulaiman SA, Abu N, Abdul Murad NA. Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines 2021;10:15. [PMID: 35052690 DOI: 10.3390/biomedicines10010015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Meyhöfer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyhöfer SM, Holl RW. Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. Diabetes Obes Metab 2022;24:727-32. [PMID: 34882949 DOI: 10.1111/dom.14616] [Reference Citation Analysis]
20 Gámez-Belmonte R, Tena-Garitaonaindia M, Hernández-Chirlaque C, Córdova S, Ceacero-Heras D, de Medina FS, Martínez-Augustin O. Deficiency in Tissue Non-Specific Alkaline Phosphatase Leads to Steatohepatitis in Mice Fed a High Fat Diet Similar to That Produced by a Methionine and Choline Deficient Diet. Int J Mol Sci 2020;22:E51. [PMID: 33374541 DOI: 10.3390/ijms22010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhao WW, Xiao M, Wu X, Li XW, Li XX, Zhao T, Yu L, Chen XQ. Ilexsaponin A1 Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice. Front Pharmacol 2021;12:771976. [PMID: 34970143 DOI: 10.3389/fphar.2021.771976] [Reference Citation Analysis]
22 Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-leon GP, Dargie NK, Carrera KG, Alemu T, Jhaveri S, Solomon N. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. [DOI: 10.7759/cureus.25495] [Reference Citation Analysis]
23 Gracen L, Hayward KL, Aikebuse M, Russell A, O'Beirne J, McPhail S, Irvine KM, Williams S, Valery PC, Powell EE. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. BMC Health Serv Res 2022;22:487. [PMID: 35413987 DOI: 10.1186/s12913-022-07808-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Roeb E. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Visc Med 2021;37:273-80. [PMID: 34540943 DOI: 10.1159/000515445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bi Y, Guo X, Zhang M, Zhu K, Shi C, Fan B, Wu Y, Yang Z, Ji G. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice. Stem Cell Res Ther 2021;12:602. [PMID: 34895322 DOI: 10.1186/s13287-021-02663-5] [Reference Citation Analysis]
26 Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest 2022. [PMID: 35303270 DOI: 10.1007/s40618-022-01766-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhao F, Ke J, Pan W, Pan H, Shen M. Synergistic effects of ISL1 and KDM6B on non-alcoholic fatty liver disease through the regulation of SNAI1. Mol Med 2022;28:12. [PMID: 35100965 DOI: 10.1186/s10020-021-00428-7] [Reference Citation Analysis]